Current stock page

Stock Analysis

Viridian Therapeutics, Inc. (VRDN) Stock Analysis

Viridian Therapeutics, Inc. (VRDN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

VRDN Stock Analysis Summary

Viridian Therapeutics, Inc. (VRDN) currently has an AIQ Score of 58/100, indicating a neutral setup. Momentum is the strongest factor at 91/100. Value is the weakest current factor at 37/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

VRDN at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$30.87
AIQ Score58/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$3.5B
P/E Ratio (TTM)-7.98
Forward P/E—
EPS (Q3 FY2026)-$0.81
Revenue (Q3 FY2026)$25.75M
Dividend Yield (TTM)0.00%
Beta1.14
Volume1.2M
52-week range$13.18-$34.29
RSI 1477.28
50-Day SMA$22.75
200-Day SMA$21.56
Analyst Price Target$40.50
Next EarningsFeb 25, 2027
As of Nov 13, 2026 · Market close

VRDNViridian Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$30.87+$0.39 (+1.28%)

Latest quote

  • Momentum
    91
  • Value
    37
  • Quality
    41
  • Risk resilience
    46
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

VRDN Stock Analysis Summary

Viridian Therapeutics, Inc. (VRDN) currently has an AIQ Score of 58/100, indicating a neutral setup. Momentum is the strongest factor at 91/100. Value is the weakest current factor at 37/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, VRDN has AIQ Score of 58/100 with Momentum base of 91/100 and fading Value at 37/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (91/100) leads while Value (37/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.28% stock move · VRDN classified in Biotechnology.

Current Evidence

NeutralVRDN is in a neutral AIQ regime; Momentum is the strongest visible factor at 91/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is VRDN Bullish or Bearish Right Now?

VRDN currently has a neutral overall setup. Momentum is the strongest factor at 91/100, while Value is weakest at 37/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 91/100.
  • - Price is +35.71% above its 50-day SMA.
  • - Analyst target implies +31.20% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (37 vs 6).
Bear Case
  • - Value is the current constraint at 37/100.
  • - Risk Resilience is weak at 46/100.

Current Consensus

VRDN's Technical Analysis Consensus is currently Strong Buy, with 37 buy, 3 neutral, and 6 sell votes. VRDN's 14-day RSI is 77.28, which places the stock in an overbought momentum range. VRDN's beta is 1.14, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in VRDN?

The largest recent change in VRDN is Momentum moving up by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+4.0
Quality
+1.0
Risk
+0.0

What Would Change the VRDN Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

VRDN Decision Framework

Public evidence layers, setup checks, and risk context for Viridian Therapeutics, Inc..

Viridian Therapeutics, Inc. (VRDN) Stock Analysis

Viridian Therapeutics, Inc. has an AIQ Score of 58/100 in a Neutral regime. Momentum is strongest at 91/100. Beta is 1.14, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextVRDN is in a Neutral AIQ regime with score 58/100.
Signal ConflictThe primary conflict is that momentum leads at 91/100 while value lags at 37/100.
Factor EvidenceMomentum 91/100 · Value 37/100 · Quality 41/100 · Risk 46/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 91/100.

TimingPass

Momentum is 91/100 and RSI (14) is 77.3.

Regime fitWait

VRDN is in a Neutral regime at 58/100.

Risk controlFail

Risk factor is 46/100 with beta 1.14 and annual volatility 71.98%.

ConflictWait

Current conflict: momentum leads at 91/100 while value lags at 37/100.

AIQ Score
58/100
Price
$30.87
Beta
1.14
RSI (14)
77.3

VRDN Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

VRDN Fundamentals

VRDN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$25.75M
Net income
-$101.21M
Free cash flow
-$93.14M
View full VRDN fundamental analysis

VRDN Technical Analysis

VRDN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
77.28
Price vs SMA-50
+35.71%
View full VRDN technical analysis

VRDN Stock Catalysts

Track VRDN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 25, 2027
Analyst target
$40.50
News items
5
View VRDN earnings and stock catalysts

VRDN Dividend Analysis

VRDN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View VRDN dividend history and analysis

VRDN Financial Data

VRDN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$25.75M
EPS
-$0.81
Periods
8
View VRDN financials

VRDN Risk Analysis

VRDN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.14
Risk score
46/100
1Y volatility
71.98%
View VRDN risk analysis

VRDN Stock News

VRDN stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read VRDN stock news

VRDN vs Biotechnology Peers

Current peer cohort: VRDN · VSTM · XENE · XERS · ZBIO. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
VRDN
Current stock
58/10037/10091/10046/1000.4371.98%Current
VSTM
Verastem, Inc.
60/10053/10089/10036/1000.3274.24%VRDN vs VSTM
XENE
Xenon Pharmaceuticals Inc.
49/100—33/10049/1000.2768.13%VRDN vs XENE
XERS
Xeris Biopharma Holdings, Inc.
78/10068/10098/10055/1001.6756.97%VRDN vs XERS
ZBIO
Zenas BioPharma, Inc.
47/10033/10078/10039/1000.2695.33%VRDN vs ZBIO
Pairwise Compare links: VSTM · XENE · XERS · ZBIOVRDN vs VSTMVRDN vs XENEVRDN vs XERSVRDN vs ZBIOCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a VRDN stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for VRDN: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-7.98
As of Nov 13, 2026
Revenue growth
-63.51%
Gross margin
92.98%
Current debt / equity
0.42
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$25.75M
Quarter net income
-$101.21M
Quarter free cash flow
-$93.14M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
77.28
MACD
2.61

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
46/100
Beta
1.14
Annual volatility
71.98%
Max drawdown
-60.63%

VRDN Stock FAQ

What is VRDN stock price today?

Viridian Therapeutics, Inc.'s current stock price is $30.87. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is VRDN bullish or bearish right now?

VRDN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is VRDN's market cap?

VRDN's market cap is $3.5B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is VRDN's current P/E ratio?

VRDN's current P/E ratio is -7.98 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is VRDN's RSI?

VRDN's 14-day RSI is 77.28 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is VRDN above its 50-day and 200-day moving averages?

VRDN is 35.71% from its 50-day SMA and 43.21% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is VRDN's next earnings date?

VRDN's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does VRDN pay a dividend?

VRDN's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.